Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines. 1998

A I Fattom, and J Sarwar, and L Basham, and S Ennifar, and R Naso
W. W. Karakawa Microbial Pathogenesis Laboratory, Nabi, Rockville, MD 20852, USA. afattom@nabi.com

Bacterial capsular polysaccharides (CP) are carbohydrate polymers comprised of repeating saccharide units. Several of these CP have side chains attached to their backbone structures. The side chains may include O-acetyl, phosphate, sialic acid, and other moieties. Those moieties represent the immunodominant epitopes and the most functional ones. The clinically significant Staphylococcus aureus type 5 CP (CP 5) and type 8 CP (CP 8) are comprised of a trisaccharide repeat unit with one O-acetyl group attached to each repeat unit. The immunogenicity of these CP and the functionality of antibodies to the backbone and the O-acetyl moieties were investigated. Immunization with the native CP conjugates (CP with 75% O-acetylation) elicited a high proportion of antibodies directed against the O-acetyl moiety. Nonetheless, all of the vaccinees produced antibodies to the backbone moieties as well. Conjugate vaccines made of de-O-acetylated CP elicited backbone antibodies only. Antibodies to both backbone and O-acetyl groups were found to be opsonic against S. aureus strains which varied in their O-acetyl content. Absorption studies with O-acetylated and de-O-acetylated CP showed that (i) native CP conjugates generated antibodies to both backbone and O-acetyl groups and (ii) O-acetylated isolates were opsonized by both populations of antibodies while the non-O-acetylated strains were predominantly opsonized by the backbone antibodies. These results suggest that S. aureus CP conjugate vaccines elicit multiple populations of antibodies with diverse specificities. Moreover, the antibodies of different specificities (backbone or O-acetyl) are all functional and efficient against the variations in bacterial CP that may occur among clinically significant S. aureus pathogenic isolates.

UI MeSH Term Description Entries
D009895 Opsonin Proteins Proteins that bind to particles and cells to increase susceptibility to PHAGOCYTOSIS, especially ANTIBODIES bound to EPITOPES that attach to FC RECEPTORS. COMPLEMENT C3B may also participate. Opsonin,Opsonin Protein,Opsonins,Protein, Opsonin
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D010659 Phenylhydrazines Diazo derivatives of aniline, used as a reagent for sugars, ketones, and aldehydes. (Dorland, 28th ed)
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide
D000107 Acetylation Formation of an acetyl derivative. (Stedman, 25th ed) Acetylations
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies
D000942 Antigens, Bacterial Substances elaborated by bacteria that have antigenic activity. Bacterial Antigen,Bacterial Antigens,Antigen, Bacterial
D012703 Serotyping Process of determining and distinguishing species of bacteria or viruses based on antigens they share. Serotypings
D013209 Staphylococcal Vaccines Vaccines, Staphylococcal

Related Publications

A I Fattom, and J Sarwar, and L Basham, and S Ennifar, and R Naso
April 2004, American heart journal,
A I Fattom, and J Sarwar, and L Basham, and S Ennifar, and R Naso
July 1984, Infection and immunity,
A I Fattom, and J Sarwar, and L Basham, and S Ennifar, and R Naso
January 1987, Annales de l'Institut Pasteur. Microbiology,
A I Fattom, and J Sarwar, and L Basham, and S Ennifar, and R Naso
July 2002, Infection and immunity,
A I Fattom, and J Sarwar, and L Basham, and S Ennifar, and R Naso
July 1990, Carbohydrate research,
A I Fattom, and J Sarwar, and L Basham, and S Ennifar, and R Naso
March 2010, Infection and immunity,
A I Fattom, and J Sarwar, and L Basham, and S Ennifar, and R Naso
July 2001, Vaccine,
A I Fattom, and J Sarwar, and L Basham, and S Ennifar, and R Naso
October 1987, Journal of clinical microbiology,
A I Fattom, and J Sarwar, and L Basham, and S Ennifar, and R Naso
August 1994, Journal of bacteriology,
A I Fattom, and J Sarwar, and L Basham, and S Ennifar, and R Naso
February 1991, Applied and environmental microbiology,
Copied contents to your clipboard!